Transient elastography (FibroScan) is a non-invasive method for evaluating liver fibrosis by measuring liver stiffness. A prospective study involving 711 patients with chronic liver disease assessed the accuracy of liver stiffness measurements in detecting cirrhosis. Liver stiffness was significantly correlated with fibrosis stage (r=0.73, p<0.0001). The area under the receiver operating characteristic (ROC) curve (AUROC) was 0.80 for significant fibrosis (F>2), 0.90 for severe fibrosis (F3), and 0.96 for cirrhosis. Using a cut-off value of 17.6 kPa, the positive and negative predictive values for cirrhosis were 90%. Liver stiffness was significantly correlated with clinical, biological, and morphological parameters of liver disease. Cut-off values for the presence of oesophageal varices stage 2/3, cirrhosis Child-Pugh B or C, past history of ascites, hepatocellular carcinoma, and oesophageal bleeding were 27.5, 37.5, 49.1, 53.7, and 62.7 kPa, respectively. The study concluded that transient elastography is a promising non-invasive method for detecting cirrhosis in patients with chronic liver disease. It is a reliable and reproducible technique that could be used for follow-up and management of these patients. Liver biopsy remains the gold standard for assessing fibrosis, but it is invasive and has limitations due to sampling error and interobserver variability. Transient elastography offers a non-invasive alternative with high diagnostic accuracy. The study demonstrated that liver stiffness measurements using FibroScan are accurate for assessing the severity of cirrhosis and could be used for screening and follow-up in clinical practice. The results indicate that liver stiffness measurement is a good method for diagnosing fibrosis and cirrhosis, regardless of the cause of liver disease. Values in cirrhotic patients ranged from 17.6 to 75.4 kPa. Liver stiffness measurement may be accurate for assessing the severity of cirrhosis. However, a longitudinal cohort study is needed to predict the complications of cirrhosis using FibroScan so that screening for complications of cirrhosis and close follow-up could be performed.Transient elastography (FibroScan) is a non-invasive method for evaluating liver fibrosis by measuring liver stiffness. A prospective study involving 711 patients with chronic liver disease assessed the accuracy of liver stiffness measurements in detecting cirrhosis. Liver stiffness was significantly correlated with fibrosis stage (r=0.73, p<0.0001). The area under the receiver operating characteristic (ROC) curve (AUROC) was 0.80 for significant fibrosis (F>2), 0.90 for severe fibrosis (F3), and 0.96 for cirrhosis. Using a cut-off value of 17.6 kPa, the positive and negative predictive values for cirrhosis were 90%. Liver stiffness was significantly correlated with clinical, biological, and morphological parameters of liver disease. Cut-off values for the presence of oesophageal varices stage 2/3, cirrhosis Child-Pugh B or C, past history of ascites, hepatocellular carcinoma, and oesophageal bleeding were 27.5, 37.5, 49.1, 53.7, and 62.7 kPa, respectively. The study concluded that transient elastography is a promising non-invasive method for detecting cirrhosis in patients with chronic liver disease. It is a reliable and reproducible technique that could be used for follow-up and management of these patients. Liver biopsy remains the gold standard for assessing fibrosis, but it is invasive and has limitations due to sampling error and interobserver variability. Transient elastography offers a non-invasive alternative with high diagnostic accuracy. The study demonstrated that liver stiffness measurements using FibroScan are accurate for assessing the severity of cirrhosis and could be used for screening and follow-up in clinical practice. The results indicate that liver stiffness measurement is a good method for diagnosing fibrosis and cirrhosis, regardless of the cause of liver disease. Values in cirrhotic patients ranged from 17.6 to 75.4 kPa. Liver stiffness measurement may be accurate for assessing the severity of cirrhosis. However, a longitudinal cohort study is needed to predict the complications of cirrhosis using FibroScan so that screening for complications of cirrhosis and close follow-up could be performed.